Innohep and Escitalopram drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Innohep and Escitalopram. Common interactions include gamma-glutamyltransferase increased among females and dyskinesia among males.

The phase IV clinical study analyzes what interactions people who take Innohep and Escitalopram have. It is created by eHealthMe based on reports of 64 people who take Innohep and Escitalopram from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

64 people who take Innohep and Escitalopram together, and have interactions are studied.

What is Innohep?

Innohep has active ingredients of tinzaparin sodium. eHealthMe is studying from 8,216 Innohep users for its effectiveness, alternative drugs and more.

What is Escitalopram?

Escitalopram has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 62,458 Escitalopram users for its effectiveness, alternative drugs and more.

Number of Innohep and Escitalopram reports submitted per year:

Common Innohep and Escitalopram drug interactions by gender *:

female:

Gamma-glutamyltransferase increased
Gastritis
Gastrointestinal toxicity
Haemoglobin decreased
Hepatitis cholestatic
Hyperkalaemia
Hypoalbuminaemia
Hyponatraemia
Hypophagia
Hypothyroidism

male:

Dyskinesia
Pleural effusion
Supraventricular tachycardia
General physical health deterioration
Acute respiratory distress syndrome
Diarrhoea
Epistaxis
Mouth haemorrhage
Musculoskeletal stiffness
Respiratory tract infection

Common Innohep and Escitalopram drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Gastrointestinal toxicity

30-39:

n/a

40-49:

Diarrhoea
Haemoglobin decreased
Phlebitis
Rectal haemorrhage

50-59:

Pulmonary embolism
Pulmonary thrombosis
Spinal cord infection
Spondylitis
Urine output decreased
Urticaria
Eczema
Sepsis
Abdominal pain upper
Alanine aminotransferase increased

60+:

Confusional state
Dyspnoea
Pneumatosis intestinalis
Sepsis
Acute respiratory distress syndrome
Bicytopenia
Cholestasis
Diarrhoea
Erythema
Facial bones fracture

Common conditions people have *:

Anaemia (lack of blood): 13 people, 20.31%
High Blood Pressure: 13 people, 20.31%
Pulmonary Embolism (blockage of the main artery of the lung): 13 people, 20.31%
Acute Kidney Failure: 10 people, 15.62%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 10 people, 15.62%
Stress And Anxiety: 9 people, 14.06%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 8 people, 12.50%
Pain: 7 people, 10.94%
Lung Neoplasm Malignant (cancer tumour of lung): 6 people, 9.38%
Heparin-Induced Thrombocytopenia: 6 people, 9.38%

* Approximation only. Some reports may have incomplete information.

Do you take Innohep and Escitalopram?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Innohep (8,216 reports)
Escitalopram (62,458 reports)